Skip to main content

Table 2 Estimation of clinical status of sarcoidosis at follow-up visit (V2).

From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up

V2 examinations


Radiology (CXR)

0. normal


1. abnormal, improved to V1


2. abnormal, no change to V1


3. worse than V1



0. FEV1/FVC>70%, other parameters ≥ 80% predicted


1. FEV1/FVC≤ 70%, at least one of the other < 80% predicted

Laboratory (SACE, CRP, S-Ca2+, U-Ca2+)

0. all within NL


1. at least one out of NL

Lofgren syndrome (EN, elevated BT, arthritis, oedema)

0. absent


1. present

General symptoms (fatigue, weight loss, sweating, arthralgia, myalgia etc)

0. absent


1. present

Respiratory symptoms (cough, breathlessness, exercise intolerance etc)

0. absent


1. present

Extrapulmonary signs and symptoms

0. absent


1. present

  1. Only patients with the sum of points at V2 = 0 were qualified as having complete remission. BT -- body temperature, DLCOc -- diffusion capacity for CO corrected for hemoglobin, EN -- erythema nodosum, FEV1 -- forced expiratory volume in 1st second of expiration, FVC -- forced vital capacity, LFT - lung function tests, NL -- normal; limits, S -- serum, SACE -- serum angiotensin converting enzyme, T -- time, U -- urine.